We are live on ! Find out more
THRX

Theseus Pharmaceuticals, Inc. Common Stock
THRX

Delisted

THRX was delisted on the 13th of February, 2024.

Back to rankings

46 hedge funds and large institutions have $441M invested in Theseus Pharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 46 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
46
Holders Change
+46
Holders Change %
–
% of All Funds
0.71%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.06%
New
46
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$254M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$82.3M
3
FCMV
Foresite Capital Management V
California
+$48.5M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$19.6M
5
BC
Boxer Capital
California
+$13.5M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$214M +$254M +16,838,668 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$69.1M +$82.3M +5,448,669 New
FCMV
3
Foresite Capital Management V
California
$40.7M +$48.5M +3,212,732 New
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$16.2M +$19.6M +1,299,487 New
BC
5
Boxer Capital
California
$11.3M +$13.5M +892,057 New
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$9.66M +$11.5M +761,589 New
OFM
7
Omega Fund Management
Massachusetts
$9.02M +$10.7M +711,479 New
Wellington Management Group
8
Wellington Management Group
Massachusetts
$7.92M +$9.43M +624,820 New
NI
9
Nextech Invest
Switzerland
$7.75M +$9.23M +611,310 New
BlackRock
10
BlackRock
New York
$6.76M +$8.05M +533,263 New
FCM
11
Farallon Capital Management
California
$6.64M +$7.91M +523,979 New
Vanguard Group
12
Vanguard Group
Pennsylvania
$6.17M +$7.35M +486,758 New
FCOMV
13
Foresite Capital Opportunity Management V
California
$5.95M +$7.08M +468,820 New
RSCM
14
Rock Springs Capital Management
Maryland
$5.54M +$6.6M +437,329 New
LCM
15
Lynx1 Capital Management
Puerto Rico
$5.19M +$6.18M +409,358 New
Ensign Peak Advisors
16
Ensign Peak Advisors
Utah
$3.17M +$3.77M +250,000 New
WP
17
Woodline Partners
California
$3.17M +$3.77M +250,000 New
LCM
18
Laurion Capital Management
New York
$2.6M +$3.1M +205,021 New
Geode Capital Management
19
Geode Capital Management
Massachusetts
$2.44M +$2.9M +192,047 New
State Street
20
State Street
Massachusetts
$1.61M +$1.91M +126,796 New
TCM
21
Tekla Capital Management
Massachusetts
$1.27M +$1.51M +100,000 New
DCM
22
DAFNA Capital Management
California
$1.24M +$1.47M +97,500 New
Northern Trust
23
Northern Trust
Illinois
$1.23M +$1.46M +96,884 New
TD Asset Management
24
TD Asset Management
Ontario, Canada
$713K +$849K +56,202 New
Charles Schwab
25
Charles Schwab
California
$393K +$467K +30,944 New
1
2

THRX Hedge Fund Activity: Q4 2021 in Review

46 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Theseus Pharmaceuticals, Inc. Common Stock (THRX) for Q4 2021, worth a combined $441M.

Buyers outnumbered sellers: 46 funds opened new THRX positions and 0 closed out — a net gain of 46 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $254M.

  • 46 institutional investors held Theseus Pharmaceuticals, Inc. Common Stock (THRX) as of Q4 2021, up from 0 in Q3 2021.
  • Funds reported $441M of Theseus Pharmaceuticals, Inc. Common Stock stock for Q4 2021.
  • 46 funds opened new Theseus Pharmaceuticals, Inc. Common Stock positions in Q4 2021 and 0 closed out, a net change of +46 holders.
  • The largest Theseus Pharmaceuticals, Inc. Common Stock buyer in Q4 2021 was OrbiMed, an estimated $254M added.

Based on aggregated 13F filings for Q4 2021.